RAVIMID PRINTERIST?⟩Tartu teadlased astusid suure sammu personaalse ravi poole

A recent investigation originating from the University of Tartu addresses the potential of 3D printing technology in pharmaceutical manufacturing. Kristiine Roostar, a junior researcher specializing in Pharmaceutical Technology at the University of Tartu, led the study to explore whether medicines can be produced using advanced additive manufacturing techniques. Currently, drug production predominantly relies on large-scale batch manufacturing processes.

However, the research suggests that 3D printing could significantly advance drug production, potentially bringing medication closer to the individual patient. This new research effort is moving toward realizing the possibility of printing drugs with unprecedented precision. The implications of this technology are substantial, pointing toward a future where pharmaceuticals can be highly customized.

By utilizing 3D printing, researchers aim to overcome the limitations of traditional methods, allowing for the precise structuring of drug compounds. This level of control could enable the creation of personalized medicines tailored to a specific patient’s needs, rather than relying on standardized dosages. The work conducted by the farmatseutilise technology department underscores a major shift in pharmaceutical science.

If successfully scaled, this method could revolutionize drug delivery, potentially improving efficacy and reducing waste. The tartu research team continues to advance this field, marking a significant sammu in making drug development more precise and patient-centric. This exploration highlights the convergence of advanced engineering and medicine, promising a new era in healthcare accessibility and drug formulation.

Topics: #tartu #sammu #farmatseutilise